Document:

<PAGE>   1
                                                                     EXHIBIT 4.6

                             REIMBURSEMENT AGREEMENT

         REIMBURSEMENT AGREEMENT, dated as of April 14, 2000 (this "Agreement"),
is by and between First Horizon Pharmaceutical Corporation, a Delaware
corporation (the "Company"), and the Kapoor Children's 1992 Trust (the "Trust").

         WITNESSETH:

         WHEREAS, the Company has entered into an Amended and Restated Loan and
Security Agreement (as amended and existing on the date hereof, the "Existing
Loan Agreement") with LaSalle Bank, N.A. (the "Lender"); and

         WHEREAS, the Company and the Lender shall enter into a third amendment
to the Existing Loan Agreement (the "Amendment") pursuant to which the Lender
shall loan to the Company $13 million (the "Bridge Loan") for the purposes set
forth in the Amendment, which loan shall be evidenced by a term note in favor of
Lender (the "Bridge Note"); and

         WHEREAS, as security for the indebtedness of the Company evidenced by
the Bridge Note, and as a condition to the Lender's entering into the Amendment,
the Trust shall on the date hereof execute a Security Agreement Re: Investment
Account (the "Pledge Agreement") in favor of Lender pursuant to which the Trust
shall, subject to the terms and conditions set forth in the Pledge Agreement,
pledge certain Collateral (as defined in the Pledge Agreement) to the Lender for
the benefit of the Company; and

         WHEREAS, the Trust has agreed to enter into the Pledge Agreement on the
terms and conditions set forth herein.

         NOW, THEREFORE, in consideration of the premises, the Company and the
Trust hereby agree as follows:

                                   ARTICLE I.

                                   DEFINITIONS

         SECTION 1.01 Certain Defined Terms. In addition to terms elsewhere
defined herein, the following terms shall have the following respective
meanings:

         "Business Day" shall mean a day other than a Saturday, Sunday or other
day on which the Lender is not open to the public for carrying on substantially
all of its banking functions in Chicago, Illinois.

         "Capital Lease" of any person shall mean any lease which, in accordance
with Generally Accepted Accounting Principles, is or should be capitalized on
the books of such person.
<PAGE>   2

         "Closing Date" shall mean the date of this Agreement which shall be the
same date as the Amendment and the Pledge Agreement are dated.

         "Code" shall mean the Internal Revenue Code of 1986, as amended from
time to time, and the regulations thereunder.

         "Contingent Liabilities" of any person shall mean, as of any date, all
obligations of such person or of others for which such person is contingently
liable, as obliger, guarantor, surety, accommodation party, partner or in any
other capacity, or in respect of which obligations such person assures a
creditor against loss or agrees to take any action to prevent any such loss
(other than endorsements of negotiable instruments for collection in the
ordinary course of business), including without limitation all reimbursement
obligations of such person in respect of any letters of credit, surety bonds or
similar obligations (including, without limitation, bankers acceptances) and all
obligations of such person to advance funds to, or to purchase assets, property
or services from, any other person in order to maintain the financial condition
of such other person.

         "Default" shall mean any event or condition which might become an Event
of Default with notice or lapse of time or both.

         "Dollars" and "$" shall mean the lawful money of the United States of
America.

         "Environmental Laws" as of any date shall mean all provisions of law,
statute, ordinances, rules, regulations, judgments, writs, injunctions, decrees,
orders, awards and standards promulgated by the government of the United States
of America or any foreign government or by any state, province, municipality or
other political subdivision thereof or therein or by any court, agency,
instrumentality, regulatory authority or commission of any of the foregoing
concerning the protection of, or regulating the discharge of substances into,
the environment.

         "ERISA" shall mean the Employee Retirement Income Security Act of 1974,
as amended from time to time, and the regulations thereunder.

         "ERISA Affiliate" shall mean, with respect to any person, any trade or
business (whether or not incorporated) which, together with such person or any
Subsidiary of such person, would be treated as a single employer under Section
414 of the Code.

         "Event of Default" shall mean any of the events or conditions described
in Section 6.01.
<PAGE>   3

         "Generally Accepted Accounting Principles" shall mean generally
accepted accounting principles applied on a basis consistent with that reflected
in the financial statements referred to in Section 4.01(g) hereof.

         "Hazardous Materials" includes, without limitation, any flammable
explosives, radioactive materials, hazardous materials, hazardous wastes,
hazardous or toxic substances or related materials defined in the Comprehensive
Environmental Response, Compensation and Liability Act of 1980, as amended (42
U.S.C. Sections 9601, et seq.), the Hazardous Materials Transportation Act, as
amended (49 U.S.C. Sections 1801, et seq.), the Resource Conservation and
Recovery Act, as amended (42 U.S.C. Sections 6901, et seq.), and in the
regulations adopted and publications promulgated pursuant thereto, or any other
federal, state or local government law, ordinance, rule or regulation.

         "Indebtedness" of any person shall mean, as of any date, (a) all
obligations of such person for borrowed money, (b) all obligations of such
person as lessee under any Capital Lease, (c) all obligations which are secured
by any Lien existing on any asset or property of such person whether or not the
obligation secured thereby shall have been assumed by such person (to the extent
of such Lien if such obligation is not assumed), (d) all obligations of such
person for the unpaid purchase price for goods, property or services acquired by
such person, except for trade accounts payable arising in the ordinary course of
business that are not past due, (e) all obligations of such person to purchase
goods, property or services where payment therefor is required regardless of
whether delivery of such goods or property or the performance of such services
is ever made or tendered (generally referred to as "take or pay contracts"), (f)
all liabilities of such person in respect of Unfunded Benefit Liabilities under
any Plan of such person or of any ERISA Affiliate, (g) all obligations of such
person in respect of any interest rate or currency swap, rate cap or other
similar transaction (valued in an amount equal to the highest termination
payment, if any, that would be payable by such person upon termination for any
reason on the date of determination), and (h) all obligations of others similar
in character to those described in clauses (a) through (g) of this definition
for which such person is contingently liable, as obliger, guarantor, surety,
accommodation party, partner or in any other capacity, or in respect of which
obligations such person assures a creditor against loss or agrees to take any
action to prevent any such loss (other than endorsements of negotiable
instruments for collection in the ordinary course of business), including
without limitation all reimbursement obligations of such person in respect of
letters of credit, surety bonds or similar obligations and all obligations of
such person to advance funds to, or to purchase assets, property or services
from, any other person in order to maintain the financial condition of such
other person.

         "Loan Agreement" shall mean the Existing Loan Agreement as amended by
the Amendment.

         "Multiemployer Plan" shall mean any "multiemployer plan" as defined in
Section 4001(a)(3) of ERISA or Section 414(f) of the Code.
<PAGE>   4

         "Operative Documents" shall mean the Existing Loan Agreement, the
Amendment, the Pledge Agreement and any other agreement or instrument relating
thereto.

         "Overdue Rate" shall mean a rate per annum equal to the sum of 300
basis points (3%) per annum plus the then effective interest rate charged by the
Lender with respect to indebtedness under the Bridge Loan.

         "Person" or "person" shall include an individual, a corporation, an
association, a partnership, a trust or estate, a joint stock company, an
unincorporated organization, a joint venture, a limited liability company, a
trade or business (whether or not incorporated), a government (foreign or
domestic) and any agency or political subdivision thereof, or any other entity.

         "Plan" shall mean, with respect to any person, any pension plan
(including a Multiemployer Plan) subject to Title IV of ERISA or to the minimum
funding standards of Section 412 of the Code which has been established or
maintained by such person, any subsidiary of such person or any ERISA Affiliate,
or by any other person if such person or any ERISA Affiliate could have
liability with respect to such pension plan.

         "Subordinated Debt" shall mean Indebtedness of the Company which is
expressly subordinated in right of payment to the Indebtedness of the Company to
the Trust hereunder in a manner satisfactory to the Trust in its sole
discretion.

         "Subsidiary" of any person shall mean any other person (whether now
existing or hereafter organized or acquired) in which (other than directors
qualifying shares required by law) at least a majority of the securities or
other ownership interests of each class having ordinary voting power or
analogous right (other than securities or other ownership interests which have
such power or right only by reason of the happening of a contingency), at the
time as of which any determination is being made, are owned, beneficially and of
record, by such person or by one or more of the other Subsidiaries of such
person or by any combination thereof. Unless otherwise specified, reference to
"Subsidiary" shall mean a Subsidiary of the Company.

         "Unfunded Benefit Liabilities" shall mean, with respect to any Plan as
of any date, the amount of the unfunded benefit liabilities determined in
accordance with Section 4001(a)(18) of ERISA.

         SECTION 1.02 Other Definitions: Rules of Construction. As used herein,
the terms "Company", "Trust", and "Agreement" shall have the respective meanings
ascribed thereto in the introductory paragraph of this Agreement. All financial
terms used herein shall be made or construed in accordance with Generally
Accepted Accounting Principles existing on the date hereof unless such
principles are inconsistent with the express requirements of this Agreement.

<PAGE>   5
Use of the terms "herein", "hereof", and "hereunder" shall be deemed references
to this Agreement in its entirety and not to the Section or clause in which such
term appears. References to "Sections" and "subsections" shall be to Sections
and subsections, respectively, of this Agreement unless otherwise specifically
provided.

                                   ARTICLE II.
                    AMOUNT AND TERMS OF THE LIMITED GUARANTY

         SECTION 2.01 Pledge Agreement. The Trust agrees, on the terms and
subject to the conditions hereinafter set forth, to execute and perform its
obligations under the Pledge Agreement for the benefit of the Lender. Execution
and delivery of the Pledge Agreement will be conditioned upon satisfaction of
the conditions precedent set forth in Section 3.01 hereof.

         SECTION 2.02 Pledge Fees. In consideration for the Trust's execution
and delivery of the Pledge Agreement, the Company agrees to make the following
payments to the Trust:

         (a) The Company shall pay to the Trust a fee of $100,000 per year,
payable quarterly in arrears on the fifteenth day of each of July, October,
January and April beginning on July 15, 2000, pro rated based on the period of
time that the Lender had a security interest or other claim with respect to
Trust assets under the Pledge Agreement during the period to which such payment
relates, provided that, until the Lender provides a written release of the
Collateral, the Lender shall be considered to have a security interest and claim
under the Pledge Agreement for purposes of this paragraph; and

         (b) The Company shall pay to the Trust any and all expenses incurred in
connection with the negotiation, documentation and execution of the Pledge
Agreement (including the Trust's legal fees) on or prior to the execution and
delivery by the Trust to the Lender of the Pledge Agreement.

         SECTION 2.03 Reimbursement. The Company shall pay to the Trust (i) on
any date on which the Trust shall be required to make a payment under the Pledge
Agreement, a sum equal to the amount so paid by the Trust, (ii) within 30 days
of demand by the Trust, any and all expenses incurred by the Trust in enforcing
or protecting any rights under this Agreement or any of the other Operative
Documents, including without limitation reasonable attorneys' fees relating to
such enforcement or protection, provided that such expenses are attributable to
the Trust's entering into or performing its obligations under the Operative
Documents to which it is a party, and (iii) forthwith upon demand by the Trust,
interest on any and all amounts remaining unpaid by the Company under this
Agreement at any time from the date any such amount becomes payable until
payment in full, at the Overdue Rate.

         SECTION 2.04 Additional Costs. In the event the Trust makes any payment
under or is otherwise required to perform any obligation under the Pledge
Agreement, the Company shall
<PAGE>   6
pay to the Trust all costs, expenses, fees and commissions incurred by the Trust
in connection with making such payment or performing such obligations to the
extent such costs, expenses, fees or commissions would not have otherwise been
incurred by the Trust but for its execution or performance of its obligations
under the Operative Documents to which it is a party.

         SECTION 2.05 Taxes; Make Whole Requirement. In the event that the Trust
incurs any federal, state or local tax liability (including any tax liability
that would otherwise have been deferred in whole or in part to some future date)
in connection with executing or performing its obligations under the Pledge
Agreement, then the Company shall pay to the Trust an amount, determined by the
Trust in its reasonable judgement, which shall put the Trust in the same
economic position as it would have been had such tax liability not been incurred
or had been deferred. The Company's liability under this Section 2.05 shall not
include capital gains taxes incurred by the Trust in connection with sales made
by the Trust not related to the performance of its obligations under the Pledge
Agreement.

         SECTION 2.06 Payments and Computations. The Company shall make each
payment hereunder in lawful money of the United States of America to the Trust
at its address referred to in Section 7.02 hereof in immediately available
funds. All computations of interest, commissions and fees hereunder shall be
made by the Trust on the basis of a year of 365 or 366 days, as the case may be,
for the actual number of days elapsed.

         SECTION 2.07 Payment on Non-Business Days. Whenever any payment to be
made hereunder shall be stated to be due on a day which is not a Business Day,
such payment may be made on the next succeeding Business Day, and such extension
of time shall in such case be included in the computation of such payment.

         SECTION 2.08 Obligations Absolute. The obligations of the Company under
this Agreement shall be absolute, unconditional and irrevocable and such
obligations of the Company shall not be affected, modified or impaired upon the
happening of any event, including, without limitation, any of the following,
whether or not with notice to, or the consent of, the Company:

         (a) Any lack of validity or enforceability of any of the Operative
Documents;

         (b) Any amendment, modification, waiver, consent, or any substitution,
exchange or release of or failure to perfect any interest in collateral or
security, with respect to any of the Operative Documents;

         (c) The existence of any claim, setoff, defense or other right which
the Company may have at any time against the Lender (or any persons or entities
for whom the Lender may be acting), the Trust or any other person or entity,
whether in connection with this Agreement, any of the Operative Documents, the
transactions contemplated herein or therein or any unrelated transactions;

<PAGE>   7

         (d) Payment by the Trust under the Pledge Agreement which does not
comply with the terms of the Pledge Agreement; provided, however, that in any
such event, upon payment in full by the Trust, the Company shall be subrogated
to the Trust's rights against the person to whom such payment was made;

         (e) Any failure, omission, delay or lack on the part of the Trust or
any party to any of the Operative Documents in enforcing, asserting or
exercising any right, power or remedy conferred upon the Trust or any such party
under this Agreement or any of the Operative Documents, or any other acts or
omissions on the part of the Trust or any such party;

         (f) The voluntary or involuntary liquidation, dissolution, sale or
other disposition of all or substantially all the assets of the Company, the
receivership, insolvency, bankruptcy, assignment for the benefit of creditors,
reorganization, arrangement, composition with creditors or readjustment or other
similar proceedings affecting the Company or any of the assets of either of
them, or any allegation or contest of the validity of this Agreement or any of
the Operative Documents, in any such proceeding;

         (g) Any other event or action that would, in the absence of this
clause, result in the release or discharge by operation of law of the Company
from the performance or observance of any obligation, covenant or agreement
contained in this Agreement;

         (h) Any action by the Trust relating to the management of the Trust's
assets which may have the effect of increasing the Company's liability to the
Trust hereunder, including the allocation of Trust assets and the liquidation of
securities in connection with any payment required under the Pledge Agreement;
or

         (i) No setoff, counterclaim, reduction or diminution of any obligation,
or any defense of any kind or nature which the Company has or may have against
the Lenders shall be available hereunder to the Company against the Trust.

                                  ARTICLE III.

                    CONDITIONS OF DELIVERY; CLOSING DOCUMENTS

         SECTION 3.01 Conditions Precedent to Execution and Delivery of the
Pledge Agreement. The obligation of the Trust to execute and deliver the Pledge
Agreement is subject to the satisfaction of the following conditions precedent:

         (a) Documents. On or before the date of execution and delivery of the
Pledge Agreement, the Trust shall have received the following documents, each in
form and substance satisfactory to the Trust:

<PAGE>   8
                  (i)   Organizational Documents. A copy of the articles of
organization of the Company and a good standing certificate, certified to a
current date by the Secretary of State of Delaware.

                  (ii)  By-laws and Corporate Authorizations. Copies of the
By-laws of the Company and corporate resolutions of the Company approving this
Agreement and the Operative Documents to which the Company is a party and the
consummation by the Company of the transactions contemplated hereby and thereby,
and copies of all other documents evidencing necessary action of the Company
with respect to this Agreement, all certified as true and correct on the Closing
Date by the Company's secretary.

                  (iii) Incumbency Certificate. A certificate of incumbency of
the Company containing, and attesting to the genuineness of, the signatures of
those officers of the Company authorized to act on behalf of the Company in
connection with the Operative Documents to which it is a party and the
consummation by the Company of the transactions contemplated thereby, certified
as true and correct as of the Closing Date by a duly authorized officer of the
Company.

                  (iv)  Consents, Approvals, Etc. Copies of all consents and
approvals necessary for the Company to enter into this Agreement, the Loan
Agreement, the Convertible Note, the Operative Documents to which the Company is
a party and the transactions contemplated herein and therein, together with a
certificate of an authorized officer of the Company dated such date of issuance
stating that such approvals are true and correct copies thereof and are in full
force and effect at such date, or if none are required a certificate to that
effect executed by an authorized officer of the Company.

                  (v)   Operative Documents. A copy of the Existing Loan
Agreement and an executed copy of the Amendment and each of the other Operative
Documents.

                  (vi)  Company Closing Certificate. A certificate of an
authorized officer of the Company as to the matters set forth in Sections
3.01(b) and (c) below.

                  (vii) Other Documents. Such other documents, instruments,
approvals or opinions (and, if requested by the Trustee, certified duplicates of
executed copies thereof) as the Trust may reasonably request.

         (b)      No Misrepresentation. The representations and warranties of
the Company contained in Article IV of this Agreement are true and correct on
and as of the Closing Date as though made on and as of such date.

         (c)      No Default. No event has occurred and is continuing, or would
result from such issuance, which constitutes a Default or an Event of Default.

<PAGE>   9

         (d) Pledge Agreement. The Lender shall have executed and delivered the
Pledge Agreement to the Trust containing terms and conditions satisfactory to
the Trust.

         (e) Counsel Approval. All of the Operative Documents shall be in form
and substance reasonably satisfactory to Burke, Warren, MacKay & Serritella,
P.C., counsel for the Trust.

         SECTION 3.02 Deliveries by the Trust. The Trust agrees to provide to
the Company copies of any documents required by the Lender in connection with
the execution and delivery of the Pledge Agreement.

                                   ARTICLE IV.

                         REPRESENTATIONS AND WARRANTIES

         SECTION 4.01 Representations and Warranties of the Company. The Company
represents and warrants to the Trust as follows:

         (a) Company Existence and Power. The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware and is duly qualified to do business, and is in good standing, in all
additional jurisdictions where such qualification is necessary under applicable
law. The Company has all requisite power to own or lease the properties used in
its business and to carry on its business as now being conducted and as proposed
to be conducted, and to execute and deliver this Agreement and the Operative
Documents to which it is party and to engage in the transactions contemplated by
this Agreement.

         (b) Company Authority. The execution, delivery and performance by the
Company of this Agreement and the Operative Documents to which it is a party do
not contravene any law or any contractual restriction binding on or affecting
it, and do not result in or require the creation of any lien, security interest
or other charge or encumbrance (except as provided in or contemplated by this
Agreement or the Loan Agreement) upon or with respect to any of its properties;
the execution, delivery and performance by the Company of this Agreement and the
Operative Documents to which it is a party have been duly authorized by all
necessary action and do not contravene the Company's articles of organization or
agreement or any contract or undertaking to which the Company is a party or by
which the Company or its property may be bound or affected.

         (c) Consents. Etc. All necessary consents, authorizations or approvals
of, or other action by, or notice to or filing with, any governmental or
regulatory authority or any

<PAGE>   10

nongovernmental person or entity required to be obtained or made by the Company
in connection with (i) the execution, delivery and performance by the Company of
this Agreement, (ii) the execution and delivery of the Loan Agreement or the
other Operative Documents, or (iii) any of the other transactions contemplated
by this Agreement or the Operative Documents.

         (d) Binding Effect. This Agreement and the Operative Documents to which
the Company is a party are legal, valid and binding obligations of the Company,
enforceable against the Company in accordance with their respective terms,
subject to applicable bankruptcy and insolvency law and general principles of
equity.

         (d) Loan Agreement. The representations and warranties of the Company
contained in the Loan Agreement are incorporated herein by reference and the
Company represents that such representations and warranties and true and correct
on the date hereof in all material respects, without consideration to any waiver
granted by the Lender.

SECTION 4.01 Representations and Warranties of the Trust. The Trust represents
that it is authorized to enter into this Agreement and the Pledge Agreement.

                                   ARTICLE V.

                            COVENANTS OF THE COMPANY

         SECTION 5.01 Affirmative Covenants. So long as the Trust has
obligations under the Pledge Agreement or the Lender has a security interest in
Trust assets pursuant to the Pledge Agreement, the Company will, unless the
Trust shall otherwise consent in writing:

         (a) Preservation of Company Existence. Etc. Do or cause to be done all
things necessary to preserve, renew and keep in full force and effect its legal
existence and its qualification in good standing in each jurisdiction in which
such qualification is necessary under applicable law, and the rights, licenses,
permits (including those required under Environmental Laws), franchises,
patents, copyrights, trademarks and trade names material to the conduct of its
businesses; and defend all of the foregoing against all claims, actions,
demands, suits or proceedings at law or in equity or by or before any
governmental instrumentality or other agency or regulatory authority.

         (b) Compliance with Laws. Etc. Comply in all material respects with all
applicable laws, rules, regulations and orders of any governmental authority,
whether federal, state, local or foreign (including without limitation, ERISA,
the Code and Environmental Laws) in effect from time to time, non-compliance
with which could materially and adversely affect the financial condition or
operations of the Company (such compliance to include, without limitation,
paying before the same become delinquent all taxes, assessments and governmental
charges imposed

<PAGE>   11
upon the Company or upon its property the non-payment of which could materially
and adversely affect the financial condition or operations of the Company)
except to the extent that compliance with any of the foregoing is then contested
in good faith and by appropriate legal proceedings and with respect to which
adequate reserves have been established on the books and records of the Company.

         (c) Maintenance of Properties: Insurance. Maintain, preserve and
protect all property that is material to the conduct of the business of the
Company and keep such property in good repair, working order and condition and
from time to time make, or cause to be made all needful and proper repairs,
renewals, additions, improvements and replacements thereto necessary in order
that the business carried on in connection therewith may be properly conducted
at all times in accordance with customary and prudent business practices for
similar businesses; and, in addition to that insurance required under the
Operative Documents, maintain in full force and effect insurance with
responsible and reputable insurance companies or associations in such amounts,
on such terms and covering such risks, including fire and other risks insured
against by extended coverage, as is usually carried by companies engaged in
similar businesses and owning similar properties similarly situated and maintain
in full force and effect public liability insurance, insurance against claims
for personal injury or death or property damage occurring in connection with any
of its activities or any properties owned, occupied or controlled by in such
amount as it shall reasonably deem necessary, and maintain such other insurance
as may be required by law.

         (d) Compliance with Loan Agreement. The Borrower shall comply in all
material respects with the agreements, covenants and terms of the Loan Agreement
and shall give the Trust prompt notice of any failure on the part of the Company
to comply with the agreements, covenants and terms of the Loan Agreement
regardless of any waiver on the part of the Lender.

         (e) Notices and Reports under Loan Agreement. To the extent the Loan
Agreement requires the Company to provide any notices, financial statements,
operating information, notices of default or other information to the Lender,
the Company shall also provide copies of such information to the Trust.

         (f) Payments. Except with respect to payments required under the Loan
Agreement, the Company agrees that any payments made to the Bank relating to the
Loan Agreement shall be applied to the Bridge Loan until it is paid in full. The
amount outstanding under the Bridge Note may not at any time be increased
without the written consent of the Trust.

         SECTION 5.02 Negative Covenants. So long as the Trust has any
obligation under the Pledge Agreement or the Lender has a security interest in
Trust assets under the Pledge Agreement, the Company will not, without the prior
written consent of the Trust:

<PAGE>   12
         (a) Indebtedness. Create, incur, assume or in any manner become liable
in respect of, or suffer to exist, any Indebtedness or enter into any lease as
lessee (whether or not a Capital Lease) other than:

             (i)   The Indebtedness under the Operative Documents and hereunder,
and other Indebtedness to the Lender;

             (ii)  Indebtedness existing on the date hereof and permitted under
the Loan Agreement; and

             (iii) Subordinated Debt which is unsecured.

         (b) Liens. Create, permit to be created or permit to exist any lien,
mortgage, encumbrance or other security interest (collectively, "Liens") with
respect to any of the Company's property other than:

             (i)   Liens in favor of the Lender; and

             (ii)  Liens existing on the date hereof and relating to
Indebtedness permitted under Section 5.02(b)(i)and (ii).

         (b) Inconsistent Agreements. Enter into any agreement containing any
provision which would be violated or breached by this Agreement or any of the
transactions contemplated hereby or by performance by the Company of its
obligations in connection therewith.

         (c) Subordinated Debt. Make any payment in violation of the terms
applicable to any Subordinated Debt.

         (d) Amendment to Loan Agreement. Agree to any modification, amendment
or other modifying agreement or understanding with respect to the Loan
Agreement.

                                   ARTICLE VI.

                                EVENTS OF DEFAULT

         SECTION 6.01 Events of Default. The occurrence of any of the following
events shall be an Event of Default hereunder unless waived by the Trust
pursuant to Section 7.01 hereof:

         (a) Nonpayment.  The Company shall fail to pay when due any amount
payable pursuant to Section 2.03, 2.04 or 2.05 hereof; or

<PAGE>   13

         (b) Misrepresentation. Any representation or warranty made by the
Company in connection with this Agreement or any of the Operative Documents
shall prove to have been incorrect in any material respect when made; or

         (c) Certain Covenants. The Company shall fail to perform or observe any
term, covenant or agreement contained in Section 5.01(a), 5.01(d) or 5.02
hereof; or

         (d) Other Defaults. The Company shall fail to perform or observe any
other term, covenant or agreement contained in this Agreement, and such failure
shall remain unremedied for 30 calendar days after written notice thereof shall
have been given to the Company by the Trust; or

         (e) Cross Default. The Company shall fail to pay any part of the
principal of, the premium, if any, or the interest on, or any other payment of
money due under the Loan Agreement or any of its other Indebtedness having a
principal balance, individually or in the aggregate, in excess of $100,000
(other than Indebtedness hereunder) beyond any period of grace provided with
respect thereto, or if the Company fails to perform or observe any other
agreement, term or condition contained in any document evidencing or securing
such Indebtedness or in any agreement or instrument under which any such
Indebtedness was issued or created, beyond any period of grace, if any, if the
effect of such default is either to cause the holder or holders thereof (or a
trustee on its or their behalf) to cause the Indebtedness to become due prior to
its stated maturity unless such default has been waived pursuant to the terms of
such other agreement; or

         (f) Operative Documents. A default (not caused by the failure of the
Trust to perform its payment obligations under the Pledge Agreement) under any
of the Operative Documents shall have occurred and be continuing without being
cured or waived pursuant thereto; or

         (g) Judgments. One or more judgments or orders for the payment of money
in an aggregate amount in excess of $100,000 shall be rendered against the
Company, or any other judgment or order (whether or not for the payment of
money) shall be rendered against the Company which causes a material adverse
change in the business, properties, operations or condition, financial or
otherwise, of the Company or which has a material adverse effect on the
legality, validity or enforceability of this Agreement or the Security
Documents, and either (i) such judgment or order shall have remained unsatisfied
and the Company shall not have taken action necessary to stay enforcement
thereof by reason of pending appeal or otherwise, prior to the expiration of the
applicable period of limitations for taking such action or, if such action shall
have been taken, a final order denying such stay shall have been rendered, or
(ii) enforcement proceedings shall have been commenced by any creditor upon any
such judgment or order; or

         (h) Insolvency. Etc. The Company shall be dissolved or liquidated (or
any judgment, order or decree therefor shall be entered), or shall generally not
pay its debts as they become due,

<PAGE>   14

or shall admit in writing its inability to pay its debts generally, or shall
make a general assignment for the benefit of creditors, or shall institute, or
there shall be instituted against the Company any proceeding or case seeking to
adjudicate it a bankrupt or insolvent or seeking liquidation, winding up,
reorganization, arrangement, adjustment, protection, relief or composition of it
or its debts under any law relating to bankruptcy, insolvency or reorganization
or relief or protection of debtors or seeking the entry of an order for relief,
or the appointment of a receiver, trustee, custodian or other similar official
for it or for any substantial part of its assets, rights, revenues or property,
and, if such proceeding is instituted against the Company and is being contested
by the Company in good faith by appropriate proceedings, such proceeding shall
remain undismissed unstayed for a period of 60 days; or the Company shall take
any action (corporate or other) to authorize or further any of the actions
described above in this subsection.

         SECTION 6.02 Remedies upon an Event of Default. If any Event of Default
shall have occurred and be continuing, the Trust may (i) if the Pledge Agreement
shall not have been executed and delivered, terminate its commitment to provide
the Pledge Agreement or (ii) in any event, exercise such other rights and
remedies as are available to the Trust under this Agreement, any of the
Operative Documents or applicable law.

         SECTION 6.03 Failure to make Payment by the Trust. If the Trust shall
fail to observe any payment obligation required by the Bank under the Pledge
Agreement, the Company's obligation to pay the fee provided for under Section
2.02(a) shall be temporarily suspended during the period of such failure,
provided that such fee shall continue to accrue and all other payment and
reimbursement obligations shall remain in full force and effect during such
period, and, provided further that any waiver or suspension by the bank of any
such payment obligation shall constitute a waiver of the Company hereunder. The
Company shall not be obligated to pay to the Trust any expenses of the Trust
hereunder to the extent such expenses are due solely to the Trust's failure to
observe any payment obligation required by the bank under the Pledge Agreement.

                                  ARTICLE VII.

                                  MISCELLANEOUS

         SECTION 7.01 Amendments. Etc. This Agreement may be amended from time
to time by the written agreement of all parties hereto. No amendment or waiver
of any provision of this Agreement nor consent to any departure by the Company
therefrom shall in any event be effective unless the same shall be in writing
and signed by the Trust, and then such amendment, waiver or consent shall be
effective only in the specific instance and for the specific purpose for which
given.
<PAGE>   15
         SECTION 7.02 Addresses for Notices. All notices and other
communications provided for hereunder shall be in writing and mailed by first
class mail, return receipt requested, by overnight delivery with a nationally
recognized carrier or personally delivered as follows:

                           If to the Company:

                              First Horizon Pharmaceutical Corporation
                              660 Hembree Parkway, Suite 106
                              Roswell, Georgia 30076
                              Attn.: Bala Venkataramin
                              Tel:
                              Fax: 770-442-9594

                           If to the Trust:

                              Kapoor Children's 1992 Trust
                              c/o EJ Financial Enterprises
                              225 E. Deerpath, Suite 250
                              Lake Forest, IL 60045
                              Attn: Kevin Harris
                              Tel: (847) 295-8665
                              Fax: (847) 295-8680

or such other address as either party may provide in writing to the other.

         SECTION 7.03 Costs, Expenses and Taxes. Subject to Section 2.02(b) of
this Agreement and the other terms of this Agreement, he Company agrees to pay
within 30 days of demand by the Trust all reasonable costs and expenses in
connection with the preparation, execution, delivery, filing, recording and
administration of this Agreement and any other documents which may be delivered
in connection with this Agreement, including, without limitation, the reasonable
fees and out-of-pocket expenses of Burke, Warren, MacKay & Serritella, P.C.,
counsel to the Trust, with respect thereto and with respect to advising the
Trust as to its rights and responsibilities under this Agreement and all
reasonable costs and expenses (including counsel fees and expenses) in
connection with the enforcement of this Agreement or the other Operative
Documents, and all other documents and instruments which may be delivered in
connection with this Agreement or the other Operative Documents.

         SECTION 7.04 Binding Effect: Assignment. This Agreement shall become
effective when it shall have been executed and delivered by the Company and the
Trust and thereafter shall be binding upon and inure to the benefit of the
Company and the Trust and their respective successors and assigns, except that
(i) the Company shall not have the right to assign its rights hereunder or any
interest herein without the prior written consent of the Trust, which will not
be

<PAGE>   16

unreasonably withheld, delayed or conditioned, and (ii) the Trust shall not have
the right to assign its rights hereunder without the prior written consent of
the Company, which will not be unreasonably withheld, delayed or conditioned
provided, however, that no consent of the Company shall be required for an
assignment of all or any part of, or any interest (divided or undivided) in, the
Trust's rights and benefits under this Agreement by the Trust to an entity
controlling, controlled by or under common control with Dr. John N. Kapoor, or
to any person who is related by blood, marriage or adoption to Dr. John N.
Kapoor, it being acknowledged that to the extent of any such assignment, such
assignee shall have the same rights and benefits against the Company hereunder
as it would have had if such assignee were the Trust hereunder.

         SECTION 7.07 Severability. Any provision of this Agreement which is
prohibited, unenforceable or not authorized in any jurisdiction shall, as to
such jurisdiction, be ineffective to the extent of such prohibition,
unenforceability or non-authorization without invalidating the remaining
provisions hereof or affecting the validity, enforceability or legality of such
provision in any other jurisdiction.

         SECTION 7.08 Governing Law. This Agreement shall be governed by, and
construed in accordance with the laws of the State of Illinois without giving
effect to choice of law principles of such State.

         SECTION 7.09 Headings. Section headings in this Agreement are included
herein for convenience of reference only and shall not constitute a part of this
Agreement for any other purpose.

         SECTION 7.10 Counterparts. This Agreement may be executed in any number
of counterparts, each of which, when so executed and delivered, shall be deemed
to be an original, but all such counterparts taken together shall constitute but
one and the same Agreement.

         SECTION 7.11 WAIVER OF JURY TRIAL. THE TRUST AND THE COMPANY, AFTER
CONSULTING OR HAVING HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL, KNOWINGLY,
VOLUNTARILY AND INTENTIONALLY WAIVE ANY RIGHT EITHER OF THEM MAY HAVE TO A TRIAL
BY JURY IN ANY LITIGATION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY
RELATED INSTRUMENT OR AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS
AGREEMENT OR ANY COURSE OF CONDUCT, DEALING, STATEMENTS (WHETHER ORAL OR
WRITTEN) OR ACTIONS OF EITHER OF THEM. NEITHER THE TRUST NOR THE COMPANY SHALL
SEEK TO CONSOLIDATE, BY COUNTERCLAIM OR OTHERWISE, ANY SUCH ACTION IN WHICH A
JURY TRIAL HAS BEEN WAIVED WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT BE
OR HAS NOT BEEN WAIVED. THESE PROVISIONS SHALL NOT BE DEEMED TO HAVE BEEN
MODIFIED IN ANY

<PAGE>   17

RESPECT OR RELINQUISHED BY EITHER THE TRUST OR THE COMPANY EXCEPT BY A WRITTEN
INSTRUMENT EXECUTED BY BOTH OF THEM.
                            [SIGNATURE PAGE FOLLOWS]

<PAGE>   18

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed and delivered by their respective representatives hereunto duly
authorized as of the date first above written.

                                   FIRST HORIZON PHARMACEUTICAL CORPORATION

                                   By:
                                      -----------------------------------------
                                   Its:
                                        ---------------------------------------

                                   KAPOOR CHILDREN'S 1992 TRUST

                                   By:
                                      -----------------------------------------
                                                 Editha Kapoor, Trustee<PAGE>   1
                                                                   EXHIBIT 10.17

                        CONFIDENTIAL TREATMENT REQUESTED

         Confidential Portions Of This Agreement Which Have Been Redacted Are
Marked With Brackets ("[****]"). The Omitted Material Has Been Filed Separately
With The Securities And Exchange Commission.

      ---------------------------------------------------------------------

                                   PONSTEL(R)

                            ASSET PURCHASE AGREEMENT

                                     between

                             WARNER-LAMBERT COMPANY

                                       and

                    FIRST HORIZON PHARMACEUTICAL CORPORATION

                           Dated as of April 10, 2000

      ---------------------------------------------------------------------

<PAGE>   2

         This ASSET PURCHASE AGREEMENT (the "Agreement") is entered into as of
April 10, 2000, by and among WARNER-LAMBERT COMPANY, a Delaware corporation with
offices at 201 Tabor Road, Morris Plains, New Jersey 07950 ("Warner-Lambert")
and FIRST HORIZON PHARMACEUTICAL CORPORATION, a Delaware corporation with
offices at 660 Hembree Parkway, Suite 106, Roswell, Georgia 30076 ("Horizon").

                                    RECITALS

          WHEREAS, Warner-Lambert is engaged in the business of manufacturing
and selling pharmaceutical products and owns certain rights related to the
product listed on Exhibit A hereto (the "Product"); and

          WHEREAS, the parties hereto intend that Warner-Lambert shall sell to
Horizon, and Horizon shall purchase from Warner-Lambert, certain assets related
to the Product upon the terms and subject to the conditions set forth in this
Agreement.

          NOW, THEREFORE, in consideration of the foregoing recitals and the
mutual promises, representations, warranties, covenants and agreements
hereinafter set forth, and intending to be legally bound, the parties do hereby
agree as follows:

                                    ARTICLE 1

                           PURCHASE AND SALE OF ASSETS

         1.1      SALE OF ASSETS. Pursuant to the terms and conditions set forth
in this Agreement, Warner-Lambert agrees to sell, convey, assign, grant,
transfer and deliver to Horizon, and Horizon agrees to purchase, acquire and
receive from Warner-Lambert on April 14, 2000 or such other date as the parties
agree upon in writing (the "Closing Date"), Warner-Lambert's entire interest in
all of the following assets related to the Product (collectively, the "Assets")
in the United States and Puerto Rico (the "Territory"):

                  1.1.1    Inventory. The inventories of finished Product
(including samples) owned by Warner-Lambert on the Closing Date and held for use
in the Territory as specified on Exhibit 1.1.1 hereto (the "Inventory");
provided, that the expiration date for such Inventory of finished Product is at
least twelve (12) months after the Closing Date. Inventory purchased by Horizon
hereunder shall be delivered to Horizon as soon as practicable after Closing but
in any event no later than fifteen (15) days thereafter;

                  1.1.2    Trademarks. All the rights in the Territory to the
trademarks listed on Exhibit 1.1.2 hereto (the "Trademarks");

                  1.1.3    Registrations. All regulatory approvals and
applications for regulatory approval for the Product in the Territory (including
the NDA for the Product) held by Warner-Lambert or its Affiliates (defined
below) (collectively, the "Registrations") set forth on Exhibit 1.1.3; provided,
however, that Warner-Lambert retains such rights under the Registrations, if
any, as may be required for Warner-Lambert to manufacture, have manufactured,
sell, market, distribute or use the Product outside the Territory.
Warner-Lambert shall deliver such Registrations to Horizon as soon as
practicable after Closing but in any event no later than forty-

                                       2
<PAGE>   3
five (45) days thereafter. As used herein: the term "Affiliate" shall mean (i)
any company or entity, more than fifty percent (50%) of whose voting stock or
participating profit interest is owned or controlled, directly or indirectly, by
a party; (ii) any company, entity or person which owns or controls, directly or
indirectly, more than fifty percent (50%) of the voting stock or participating
profit interest of a party and (iii) any company, entity or person which is
under common control with a party hereto and the term "common control" means a
third party has direct or indirect ownership of fifty percent (50%) or more of
the voting stock or participating profit interest of both the other company or
entity and the party to this Agreement; and "NDA" means the new drug application
for the Product set forth in Exhibit 1.1.3;

                  1.1.4    Information and Know-How. All technical information
(including the master batch record, analytical methods including validation
protocol, and the drug master file), know-how, market research results, and the
like specifically relating to the manufacture, packaging, testing, development,
distribution, marketing, use or sale of the Product (including the raw materials
used in the manufacture thereof) in the Territory owned or possessed by
Warner-Lambert on the Closing Date (collectively, the "Information"). The
Information, to the extent such Information has not previously been provided to
Horizon, shall be transferred as soon as practicable after the Closing Date, but
in any event no later than sixty (60) days thereafter;

                  1.1.5    Managed Care Agreements. To the extent their
assignment in part is permitted under the terms thereof or by the other party
thereto, all Managed Care Agreements (as hereinafter defined), to which
Warner-Lambert is a party and which are utilized in connection with the sale of
the Product by Warner-Lambert in the Territory; and

                  1.1.6    Goodwill. All goodwill associated with the Product in
the Territory other than goodwill associated with any trademark. trade name,
service mark, service name, slogan or logo used by Warner-Lambert prior to the
date hereof and not transferred to Horizon pursuant to this Agreement or any of
the other operative agreements which are necessary to completely sell, convey,
assign, grant, transfer and deliver the Assets to Horizon.

         1.2      EXCLUDED ASSETS. Notwithstanding anything in this Agreement to
the contrary, the following assets of Warner-Lambert (the "Excluded Assets")
shall be excluded from and shall not constitute Assets:

                  1.2.1    Accounts Receivable. All trade accounts receivable
and all notes, bonds and other evidences of indebtedness and rights to receive
payments arising out of sales of the Product prior to the Closing Date,
including any rights of Warner-Lambert with respect to any third party
collection procedures or any contract or any other actions which have accrued
prior to the Closing Date in connection with the manufacture, sale or use of any
Product;

                  1.2.2    Litigation Claims. Any rights (including
indemnification), claims and recoveries under litigation of Warner-Lambert or
its Affiliates against third parties arising out of or relating to events
occurring prior to the Closing Date;

                  1.2.3    Excluded Contract Rights. The rights of
Warner-Lambert or any of its Affiliates in, to and under all contracts of any
nature, the obligations of Warner-Lambert or any of its Affiliates under which
are not expressly assumed by Horizon herein; and

                                       3
<PAGE>   4

                  1.2.4    Excluded Intellectual Property. Warner-Lambert shall
retain the right and title to any Intellectual Property (as defined herein) and
Information utilized in connection with the manufacture, packaging, testing,
development, distribution, marketing, use or sale of the Product outside of the
Territory and of any of Warner-Lambert's or its Affiliates' products, other than
the Product, including, but not limited to, those that are also used by
Warner-Lambert on the Product, such as the Parke-Davis trademark, logo and
designs. As used herein "Intellectual Property" means, with respect to the
Product, all of the following without limitation and whether registered, issued,
pending or in a draft form: all patents, trademarks and trademark rights,
service marks and service mark rights, service names and service name rights,
brand names, logos, slogans, trade secrets, trade dress, processes, designs,
methodologies, technical information and know-how, in each case relating to the
manufacture, packaging, development, testing, distribution, marketing, use or
sale of such Product.

         1.3      ASSUMED LIABILITIES. Horizon shall assume and agrees to pay,
perform and discharge when due the following liabilities and obligations of
Warner-Lambert arising in connection with the Product (the "Assumed
Liabilities"):

                  1.3.1    Returns. All liabilities and obligations with respect
to (i) the returned units of the Product, from and after the date that is six
(6) months after the Closing Date and (ii) the returned units of the Product
during the first six (6) months following the Closing Date to the extent such
returns exceed 4.6% of the gross sales of the Product in the Territory in the
first six (6) months immediately preceding the Closing Date;

                  1.3.2    Rebates and Chargebacks. All liabilities and
obligations arising from (i) all rebates to state Medicaid and other state and
local governmental programs and to pharmacy benefit management companies, health
plans, insurance companies, mail service pharmacies and other health care
providers based upon the utilization of the Product (collectively, "Rebates")
and (ii) all credits, chargebacks, reimbursements, administrative fees and other
payments to wholesalers and other distributors, group purchasing organizations,
insurers and other institutions (collectively, "Chargebacks") , occurring in the
third calendar quarter of 2000 and thereafter, subject to the Rebate and
Chargeback Reimbursement (defined below) to be paid to Horizon by
Warner-Lambert, provided, however, that Horizon shall not be liable for any
Chargebacks or Rebates occurring in the first and second calendar quarters of
2000. For purposes of this Section 1.3.2, Rebates shall be deemed to have
occurred in the calendar quarter in which the pharmacy or other applicable
entity is reimbursed by Medicaid or other applicable entity and Chargebacks
shall be deemed to have occurred in the calendar quarter in which the wholesaler
or other applicable entity ships the Product that results in the chargeback. As
used herein, "Rebate and Chargeback Reimbursement" shall mean an amount equal to
the product of (i) the Rebates and Chargebacks occurring in the third calendar
quarter of 2000 and (ii) a fraction, the denominator of which is 92 and the
numerator of which is the number of days elapsed in the second quarter through
the Closing Date. To the extent that Warner-Lambert is unable to assign any
agreement of Warner-Lambert for the payment of Rebates and Chargebacks ("Managed
Care Agreements")to Horizon with respect to the Product, Horizon agrees to
reimburse Warner-Lambert for the amount of such Rebates and Chargebacks under
the Managed Care Agreements paid by Warner-Lambert within thirty (30) days after
receipt by Horizon of a written invoice from Warner-Lambert for same;

                  1.3.3    Registrations. All liabilities and obligations with
respect to the Registrations arising or incurred from and after the Closing
Date, provided, however, with

                                       4
<PAGE>   5

respect to the NDA establishment fee, Horizon shall only be responsible for such
fees which are incurred in connection with the period beginning with the first
full calendar year following the expiration or earlier termination of the Supply
Agreement (as defined herein);

                  1.3.4    Recalls. From and after the Closing Date, all
liabilities, obligations and responsibilities relating to voluntary and
involuntary recalls of Product sold by Horizon after the Closing Date, except to
the extent that such recall is for a failure of the Inventory to meet the
product specifications set forth in the NDA as such specifications exist on the
date hereof (the "Specifications"), where such failure is due solely to the
actions or omissions of Warner-Lambert;

                  1.3.5    Product Liability. From and after the Closing Date,
all liabilities, obligations and responsibilities relating to product liability
claims or threatened claims relating to Product sold by Horizon after the
Closing Date, other than product liability that results from a failure of the
Inventory to meet the Specifications, where such failure is due solely to the
actions or omissions of Warner-Lambert;

                  1.3.6    Research and Development. All liabilities,
obligations and responsibilities for any research and development conducted by
Horizon and relating to the Product after the Closing Date; and

                  1.3.7    Product Regulatory Obligations. All liabilities,
obligations and responsibilities undertaken by Horizon pursuant to Section 5.4.

         1.4      RETAINED LIABILITIES. Except for the Assumed Liabilities,
Horizon shall not assume by virtue of this Agreement or the transactions
contemplated hereby, and shall have no liability for, any liabilities, debts or
obligations of Warner-Lambert of any kind, character or description whatsoever
(the "Retained Liabilities").

                                    ARTICLE 2

                      CONSIDERATION FOR TRANSFER OF ASSETS

         2.1      PURCHASE PRICE. (a) Subject to the terms and conditions of
this Agreement, in consideration for the sale and transfer of the Assets,
Horizon shall pay to Warner-Lambert (i) a non-refundable payment of Nine Million
Five Hundred Thousand Dollars ($9,500,000) payable to Warner-Lambert on the
Closing Date, (ii) Three Million Five Hundred Thousand Dollars ($3,500,000)
payable to Warner-Lambert on the earliest of (A) three (3) Business Days
following signing of a definitive asset purchase agreement by Warner-Lambert and
a party other than Horizon regarding Warner-Lambert's Cognex business, (B) three
(3) Business Days following the date on which Horizon notifies Warner-Lambert
that it does not intend to purchase Warner-Lambert's Cognex business, (C) June
1, 2000, in the event that Horizon has not purchased Warner-Lambert's Cognex
business by such date, other than due to a delay in receiving clearance from the
Federal Trade Commission to proceed with the purchase of the Cognex business,
(D) three (3) Business Days following the date on which a definitive agreement
between Horizon and Warner-Lambert for the Cognex Business is terminated, (E)
three (3) Business Days following the date of the initial public offering of
Horizon or (F) November 30, 2000, as evidenced by an interest-free promissory
note in the form of Exhibit 2.4.2 and (iii) an

                                       5
<PAGE>   6
amount equal to the value of the Inventory transferred to Horizon pursuant to
the terms of this Agreement based on the Closing Inventory Value (as defined
below) payable to Warner-Lambert within thirty (30) days after the Closing Date.
The amounts set forth in Section 2.1 (a)(i), (ii) and (iii) are hereinafter
referred to collectively as the "Purchase Price". As used herein, "Business Day"
means a day during which banks are generally open for business in New York and
"Closing Inventory Value" means the value of the Inventory (including samples)
as of the Closing Date based on Warner-Lambert's calculation of the standard
cost of the Product.

         (b)      All payments under this Section shall be made by wire transfer
or other immediately available funds to an account indicated by Warner-Lambert.

         2.2      ALLOCATION. The parties agree to allocate the portion of the
Purchase Price paid pursuant to Sections 2.1(a)(i) and 2.1(a)(ii) among the
Assets (other than Inventory) purchased hereunder. The allocation of the
Purchase Price to Inventory shall be the amount calculated as Closing Inventory
Value in accordance with Section 2.1(a)(iii).

         2.3      CLOSING. The Closing shall take place at 11:00 a.m. EDT at 201
Tabor Road, Morris Plains, New Jersey on the Closing Date or at such time and
place as the parties hereto may otherwise mutually agree.

                                    ARTICLE 3

                         REPRESENTATIONS AND WARRANTIES

         3.1      LEGAL AUTHORITY. Each party represents and warrants that it
has the legal power, authority and right to enter into this Agreement and to
perform its respective obligations set forth herein.

         3.2      NO CONFLICTS. Each party represents and warrants that it is
not a party to any agreement or arrangement with any third party or under any
obligation or restriction, including pursuant to its Articles of Incorporation,
By-Laws or other organizational documents, which in any way limits or conflicts
with its ability to fulfill any of its obligations set forth herein.

         3.3      TITLE TO ASSETS. Warner-Lambert hereby represents and warrants
that to its knowledge: (i) it or its Affiliates has good and marketable title to
the Assets, free and clear of all liens; (ii) no sublicenses have been granted
to any third party with respect to the Assets; and (iii) there are no adverse
claims of ownership to the Assets.

         3.4      INTELLECTUAL PROPERTY RIGHTS. Warner-Lambert hereby represents
and warrants that, to its knowledge without any inquiry of third parties, there
are no patents, trademarks, trade names or copyrights or any other proprietary
rights of any third person which would be infringed by the manufacture, use or
sale of the Product in the Territory.

         3.5      INVENTORY. The Inventory will be of salable quality, will meet
the Specifications, have been manufactured in accordance with current good
manufacturing practices and other applicable law.

                                       6
<PAGE>   7

         3.6      LITIGATION. (a) Warner-Lambert hereby represents and warrants
that, to its knowledge, there is no litigation, action, suit, inquiry,
investigation, arbitration or other proceeding pending or threatened against
Warner-Lambert or its Affiliates specifically with respect to the Product, the
Assets or Warner-Lambert's right and ability to consummate the transaction
contemplated by this Agreement, nor does Warner-Lambert know of any basis for
any such proceedings, investigations or inquiries.

         (b)      Horizon hereby represents and warrants that, to its knowledge,
there is no litigation, action, suit, inquiry, investigation, arbitration or
other proceeding pending or threatened against Horizon with respect to its right
and ability to consummate the transactions contemplated by this Agreement.

         3.7      CONSENTS AND APPROVALS. Warner-Lambert and Horizon each hereby
represents and warrants that it has obtained all third party consents and
government approvals, if any, required in connection with the assignment and
assumption of the Assets to and by Horizon. Notwithstanding the foregoing, the
parties acknowledge that transfer of the NDAs will not be completed until
receipt and acceptance by the United States Food and Drug Administration ("FDA")
of the Warner-Lambert Assignment Letters and the Horizon Assumption Letters.

         3.8      HORIZON'S REPRESENTATION AND WARRANTY REGARDING THE PRODUCT.
Horizon represents and warrants that it and its Affiliates have not
manufactured, used or sold the Product anywhere worldwide or used the Trademarks
anywhere worldwide prior to the Closing Date. Horizon hereby acknowledges that
it has been afforded the opportunity to conduct due diligence with respect to
the Product and to secure such information from Warner-Lambert with respect to
the Product as it deems necessary to evaluate the merits of entering into the
transactions contemplated in this Agreement.

         3.9      NO BROKERAGE FEE. Each party represents and warrants that no
broker, financial advisor or other person or entity is entitled to any brokerage
fee or commission in respect of the execution of this Agreement or the
consummation of the transactions contemplated hereby.

         3.10     MANAGED CARE AGREEMENTS. Warner-Lambert represents and
warrants that the agreements of Warner-Lambert with the customers listed on
Exhibit 3.10 hereto are all the Managed Care Agreements as of April 10, 2000.
Also set forth on Exhibit 3.10 are the rebate and/or discount terms with respect
to each such Managed Care Agreement as of April 10, 2000. Warner-Lambert shall
deliver a revised Exhibit 3.10 at the Closing listing all the Managed Care
Agreements as of the Closing Date. Each party will use its best efforts to
notify the customers set forth on Exhibit 3.10 that the Product has been
transferred to Horizon within three (3) Business Days after the Closing Date.
Promptly after the Closing Date, but in no event later than ten (10) Business
Days following the Closing Date, Warner-Lambert shall, subject to the required
consent of the applicable customer, assign all Managed Care Agreements existing
on the Closing Date and shall notify Horizon on a regular basis regarding each
such consent and assignment; provided, however, that with respect to those
Managed Care Agreements that Warner-Lambert is unable to assign, Warner-Lambert
shall fulfill all its obligations under each such Managed Care Agreement until
its expiration (it being understood and agreed that Horizon has an obligation to
reimburse Warner-Lambert for Rebates and Chargebacks with respect to the Managed
Care Agreements pursuant to Section 1.3.2 hereof).

                                       7
<PAGE>   8

         3.11     REGISTRATIONS. Warner-Lambert hereby represents and warrants
that, to its knowledge, (i) the Registrations are in good standing and (ii)
there is no pending or threatened action by the FDA which will have a material
adverse effect on the Registrations. Warner-Lambert has paid the NDA maintenance
fee for the Product for the year 2000. It is understood and agreed by the
parties that if USP publishes a monograph covering the Product, the Product may
not meet the new USP specifications. Under those circumstances, the Product must
be labeled accordingly.

         3.12     CERTAIN FINANCIAL INFORMATION. Warner-Lambert represents and
warrants that certain 1999 financial information provided to Horizon as of
December 31, 1999, specifically, the gross sales, net sales, standard cost of
goods and gross profit of the Product in the Territory were based upon the
information contained in the books and records of Warner-Lambert and, as such,
are accurate in all material respects. As used herein, "net sales" shall mean
the aggregate sales of Warner-Lambert and its Affiliates of Product to
unaffiliated third parties in the Territory (but not including sales between
Warner-Lambert and its Affiliates) less (i) bad debts related to the Product,
and (ii) sales returns and allowances, including, without limitation, trade,
quantity and cash discounts and any other adjustments, including, but not
limited to, those granted on account of price adjustments, billing errors,
rejected goods, damaged goods, recalls, returns, rebates, chargeback rebates,
fees, reimbursements or similar payments granted or given to wholesalers or
other distributors, buying groups, health care insurance carriers or other
institutions, freight and insurance charges billed to the customers, customs or
excise duties, sales tax and other taxes (except income taxes) or duties
relating to sales, and any payment in respect of sales to any governmental or
regulatory authority in respect of any Federal or state Medicaid, Medicare or
similar program, all as determined in a manner consistent with the books and
records of Warner-Lambert.

         3.13     DISCLAIMER OF WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED HEREIN,
WARNER-LAMBERT DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH REGARD
TO THE PRODUCTS, INCLUDING THE WARRANTY OF MERCHANTABILITY AND THE WARRANTY OF
FITNESS FOR A PARTICULAR PURPOSE. WITHOUT LIMITING THE FOREGOING, HORIZON
ACKNOWLEDGES THAT WARNER-LAMBERT HAS MADE NO REPRESENTATION OR WARRANTY AS TO
THE ABILITY TO MANUFACTURE OR SELL ANY OF THE PRODUCTS IN ACCORDANCE WITH
APPLICABLE LAW.

                                    ARTICLE 4

                                 INDEMNIFICATION

         4.1      INDEMNIFICATION BY WARNER-LAMBERT. Warner-Lambert shall
indemnify, defend and hold harmless Horizon against any loss, expense, liability
or other damages, including reasonable costs of investigation, interest,
penalties and attorneys' fees (collectively, "Losses") incurred by Horizon, its
Affiliates or any of their respective officers, directors, agents or employees
(collectively, the "Horizon Group") to the extent relating to or resulting from
(a) any inaccuracy of a representation or breach of a warranty made by
Warner-Lambert in this Agreement or (b) the Retained Liabilities; provided,
however, that Warner-Lambert will have no obligations under this Section for
Losses to the extent that they are caused by (i) any inaccuracy of a
representation or breach of a warranty made by Horizon in this Agreement or (ii)
the gross

                                       8
<PAGE>   9

negligence or willful misconduct of any member of the Horizon Group. Horizon
hereby agrees that Warner-Lambert's liability under this Agreement from whatever
cause, whether pursuant to this Section or any other cause arising under this
Agreement, is limited to the amounts paid by Horizon to Warner-Lambert pursuant
to Section 2.1 as of the date of determination of such liability, provided,
however, that the limitation on liability contained in this sentence shall not
apply to a failure of the Inventory to meet the Specifications, where such
failure was due solely to the actions or omissions of Warner-Lambert.
Furthermore, the parties agree that in no event will Warner-Lambert be liable to
Horizon hereunder for special, consequential, indirect, punitive or similar
damages.

         4.2      INDEMNIFICATION BY HORIZON. Horizon shall indemnify, defend
and hold harmless Warner-Lambert against any Losses incurred by Warner-Lambert,
its Affiliates or any of their respective officers, directors, agents or
employees (collectively, the "Warner Group") relating to or resulting from (a)
any inaccuracy of a representation or breach of a warranty made by Horizon in
this Agreement; (b) any liabilities, obligations, commitments of, or claims
against any member of the Warner Group based on the manufacture, use or sale of
the Product in the Territory or use of the Trademarks or the Registrations in
the Territory, on and after the Closing Date; and (c) the Assumed Liabilities;
provided, however, that Horizon will have no obligations under this Section for
Losses to the extent that they are caused by (a) any inaccuracy of a
representation or breach of a warranty made by Warner-Lambert in this Agreement
or (b) the gross negligence or willful misconduct of any member of the Warner
Group. Furthermore, the parties agree that in no event will Horizon be liable to
Warner-Lambert hereunder for special, consequential, indirect, punitive or
similar damages.

         4.3      INDEMNIFICATION PROCEDURES. In any case under this Agreement
where one party has indemnified the other against any claim or legal action,
indemnification will be conditioned on compliance with the procedure outlined
below. Provided that prompt notice is given of any claim or suit for which
indemnification might be claimed, the indemnifying party promptly will defend,
contest or otherwise protect against any such claim or suit (including by way of
settlement and release) at its own cost and expense. The indemnified party may,
but will not be obligated to, participate at its own expense in a defense
thereof by counsel of its own choosing, but the indemnifying party will be
entitled to control the defense unless the indemnified party has relieved the
indemnifying party from liability with respect to the particular matter. If the
indemnifying party fails timely to defend, contest or otherwise protect against
any such claim or suit, the indemnified party may, but will not be obligated to,
defend, contest or otherwise protect against the same, and make any compromise
or settlement thereof and recover the entire costs thereof from the indemnifying
party, including reasonable attorneys fees, disbursements and all amounts paid
as a result of such claim or suit or the compromise or settlement thereof;
provided, however, that if the indemnifying party undertakes the timely defense
of such matter, the indemnified party will not be entitled to recover from the
indemnifying party its costs incurred in the defense thereof. The indemnified
party will cooperate and provide such assistance as the indemnifying party may
reasonably request in connection with the defense of the matter subject to
indemnification.

                                       9
<PAGE>   10

                                    ARTICLE 5

                              ADDITIONAL AGREEMENTS

         5.1      TERRITORIAL RESTRICTION. Horizon shall not directly or
indirectly sell the Product outside the Territory at any time. Horizon will use
its commercially reasonable efforts to prevent the Product from being resold for
use or sale outside the Territory. Warner-Lambert shall not directly or
indirectly sell the Product in the Territory at any time after the Closing Date.
Warner-Lambert will use its commercially reasonable efforts to prevent the
Product from being resold for use or sale in the Territory. The restrictions set
forth in this Section 5.1 shall survive indefinitely.

         5.2      USE OF WARNER-LAMBERT NAME. (a) Horizon shall not use the name
of Warner-Lambert, Parke-Davis or any of Warner-Lambert's Affiliates
(collectively, the "Warner-Lambert Name") in any manner whatsoever in connection
with the manufacture, use, sale, promotion, advertising or distribution of the
Product after the Closing Date, provided, however, Horizon may use the Inventory
purchased from Warner-Lambert by Horizon hereunder bearing the Warner-Lambert
Name (including inventory purchased under the Supply Agreement) for ten (10)
months following the Closing Date or until such Inventory is depleted, whichever
occurs first ("Final Inventory Sell Off Date"). Except as otherwise set forth in
this Section 5.2 or in Section 5.3 hereof, Horizon shall have no right to use
the Warner-Lambert Name without the prior written consent of Warner-Lambert.

         (b)      Horizon hereby agrees that any Inventory purchased from
Warner-Lambert hereunder and bearing the Warner-Lambert Name will be held,
maintained and distributed in accordance with applicable pharmaceutical current
good manufacturing practices, the Registrations, and all applicable laws.
Warner-Lambert shall have no responsibility for costs and expenses associated
with any recall of the Inventory on or after the Closing Date attributable to a
determination by a governmental or regulatory authority that the use of the
Warner-Lambert Name on such Inventory would constitute misbranding within the
meaning of the Federal Food, Drug, and Cosmetic Act.

         5.3      USE OF PROMOTIONAL MATERIALS. From the Closing Date until the
Final Inventory Sell Off Date, Horizon shall have the right, subject to
Warner-Lambert's prior written consent, to apply the Warner-Lambert Name on any
new promotional materials (including, but not limited to, journal ads,
convention materials, sales aids, and medical education materials) for the
Product. Horizon shall submit such promotional materials in final form, together
will all data and documentation required to support any claims made therein, to
Warner-Lambert's regulatory group which shall determine, within ten (10)
Business Days after receipt, whether to grant written consent to use such
promotional materials. Horizon shall have no other right to use the
Warner-Lambert Name other than as set forth herein and in Section 5.2 above.
Horizon agrees that after the Final Inventory Sell Off Date all promotional
materials containing the Warner-Lambert Name shall be destroyed at Horizon's
sole cost and expense. Use of the Warner-Lambert Name on promotional materials
by Horizon shall be at Horizon's risk.

         5.4      PRODUCT REGULATORY OBLIGATIONS.

                  5.4.1.   FDA Contacts. On and after the Closing Date, Horizon
shall be responsible for all contacts with the FDA and other regulatory
authorities in the Territory with

                                       10
<PAGE>   11

respect to the Product, and all other responsibilities under the Registrations;
provided that either party shall notify the other party immediately, and in no
event later than (A) forty-eight (48) hours after receipt of any contact or
communication from the FDA or any other governmental or regulatory authority in
the Territory and (B) five (5) Business Days after receipt of any contact or
communication with any other third party in the Territory, that in either case,
in any way requests or suggests the need for a recall or withdrawal of a lot of
Product manufactured by or on behalf of Warner-Lambert or otherwise calls into
question the quality or safety of such a Product lot. Horizon shall be
responsible for investigating any such request or suggestion and for any
communications with any governmental or regulatory authority in the Territory
relating thereto; provided that Horizon shall comply with all reasonable
requests by Warner-Lambert.

                  5.4.2.   Customer Complaints. Horizon shall be solely
responsible for responding to any Product complaint received on or after the
Closing Date concerning Product lots sold in the Territory. Each party shall
notify the other in the event that such a party receives a report of a Product
complaint relating to a Product lot manufactured by or on behalf of
Warner-Lambert. The complaint recipient shall use all reasonable efforts to
provide such notice to the other party within forty-eight (48) hours if the
complaint involves allegations of suspected or actual product tampering,
contamination or mislabeling, and shall provide such notice to the other party
within five (5) Business Days in the case of all other complaints. Horizon shall
be responsible for investigating all such Product complaints and responding to
the complainant, provided each party shall comply with all reasonable requests
from the other in connection therewith.

                  5.4.3.   Adverse Event Reporting. On and after the Closing
Date, each party shall have a continuing obligation to notify the other party of
any adverse drug experience reported to such party arising from or in connection
with the use of the Product. This notification shall occur within seventy-two
(72) hours for an unexpected fatal or life-threatening serious adverse drug
experience (as defined in 21 CFR 312.32) associated with the Product and arising
during clinical trials. For post-marketing adverse drug experience reports, the
parties agree as follows:

         (i)      Warner-Lambert shall report to Horizon all adverse drug
                  experiences arising in the Territory and all serious adverse
                  drug experience reports arising outside the Territory within
                  five (5) Business Days after the time such report becomes
                  known to any employee, agent or Affiliate of Warner-Lambert.
                  All other post-marketing adverse drug experience reports for
                  the Product shall be reported to Horizon by Warner-Lambert on
                  a rolling fifteen (15)-day basis.

         (ii)     Horizon shall report to Warner-Lambert all serious adverse
                  drug experience reports for the Product within five (5)
                  Business Days after the time such report becomes known to any
                  employee, agent or Affiliate of Horizon and all other adverse
                  drug experience reports for the Product on a rolling fifteen
                  (15)-day basis.

All notifications pursuant to this paragraph shall be by fax or e-mail at such
numbers (or e-mail addresses) agreed upon by the parties' respective drug safety
organizations. Horizon shall have sole responsibility to investigate such
adverse experience reports arising in the Territory and for reporting such
reports to governmental and regulatory authorities in the Territory.
Warner-Lambert shall have sole responsibility for investigating such adverse
experience reports arising outside the Territory and for reporting such reports
to applicable governmental and regulatory authorities outside the Territory.
Except as otherwise stated above, the terms

                                       11
<PAGE>   12

"adverse drug experience" and "serious adverse drug experience" used in this
paragraph shall have the meanings set forth in 21 CFR 314.80.

The parties shall use reasonable efforts to enter into a separate drug safety
sharing agreement describing the procedures and other logistics to implement the
provisions in this Section 5.4 within ninety (90) days after execution of this
Agreement.

                  5.4.4    Assistance with Regulatory Obligations Transfer. For
a period of up to sixty (60) days following the Closing Date, Warner-Lambert
agrees to provide assistance and cooperation reasonably requested by Horizon in
connection with the transfer of the Registrations to Horizon.

         5.5      PAYMENT OF TRANSACTION EXPENSES. All sales taxes, use taxes,
transfer taxes, filing fees (including trademark assignment fees) and similar
taxes, fees, charges and expenses (excluding any taxes arising from income or
gains earned by Warner-Lambert) required to be paid in connection with the sale
of the Assets to Horizon will be borne and paid by Horizon. All legal fees and
other expenses incurred on behalf of Warner-Lambert in connection with the
negotiation of this Agreement will be borne by Warner-Lambert; and all legal
fees and other expenses incurred on behalf of Horizon in connection with the
negotiation of this Agreement will be borne by Horizon.

         5.6      ACCESS TO WARNER-LAMBERT RECORDS. To the extent required by
the Securities and Exchange Commission in connection with an initial public
offering of or other financing for Horizon and upon five (5) Business Days'
prior written notice from Horizon, Warner-Lambert agrees to provide Horizon and
up to two (2) employees of an independent accounting firm designated by Horizon
with reasonable access to financial records pertaining to the Product covering a
period ending not more than three (3) years prior to the date of such request.
Prior to granting any access to such records, the designated accounting firm
shall first agree not to disclose any confidential information contained in such
financial records. Horizon shall pay all costs and expenses in connection with
the review of such financial records.

         5.7      LIMITATION ON TRANSFER. Horizon hereby agrees that until such
time as Horizon has discharged all its payment obligations hereunder, it shall
not convey, sell, assign, transfer, license or otherwise dispose of any of the
Assets (other than Inventory in the ordinary course of business) without the
prior written consent of Warner-Lambert, which consent shall not be unreasonably
withheld, provided, that Horizon shall have the right to assign its rights and
obligations under this Agreement to any third party successor to all or
substantially all of its entire business. Warner-Lambert will respond to such
written request for transfer of the Assets within forty-five (45) days after
receipt of such written request from Horizon.

         5.8      CONFIDENTIALITY. For a period of five (5) years from the
Closing Date, each party shall hold in confidence and use its best efforts to
have all of their respective Affiliates and representatives hold in confidence
all confidential information of the other party, and, except as contemplated by
this Agreement, shall not disclose, publish, use or permit others to use the
same; provided, however, that the foregoing restriction shall not apply to any
portion of the foregoing which was or becomes available on a non-confidential
basis to the other party or when such disclosure is required by a governmental
or regulatory authority or is otherwise required by law or is necessary in order
to establish rights under this Agreement or any other agreements referred to
herein. In the event the transaction contemplated hereby is not

                                       12
<PAGE>   13
consummated, upon the request of the other party, each party hereto will, and
will cause its Affiliates, any Person who has provided, or who is providing,
financing to such party and their respective Representatives to, promptly (and
in no event later than five (5) Business Days after such request) redeliver or
cause to be redelivered all copies of confidential documents and information
furnished by the other party in connection with this Agreement or the
transactions contemplated hereby and destroy or cause to be destroyed all notes,
memoranda, summaries, analyses, compilations and other writings related thereto
or based thereon prepared by the party furnished such documents and information
or its representatives, provided, however, that each party shall be entitled to
keep one archival copy of such confidential documents and information and
related materials solely as evidence of what was redelivered and destroyed
hereunder, and for no other purpose.

         5.9      TECHNICAL TRANSFER. Subsequent to the Closing Date,
Warner-Lambert agrees to provide the technical support, to the extent possible,
set forth on Exhibit 5.9 attached hereto. Horizon shall pay to Warner-Lambert
the amounts set forth on Exhibit 5.9 for all technical support provided by
Warner-Lambert. In addition, the parties agree to use their best efforts to
agree upon a systems transfer plan within thirty (30) days after the Closing
Date.

         5.10     FURTHER ASSURANCES. Warner-Lambert, at any time after the
Closing Date, at the request of Horizon and at Horizon's sole expense, shall
execute, acknowledge and deliver any further assignments, and other assurances,
documents and instruments of transfer that may be reasonably necessary for the
purpose of assigning and granting to Horizon all Assets to be conveyed pursuant
to this Agreement.

         5.11     THIRD PARTY CONSENTS. To the extent that any Managed Care
Contract is not assignable without the consent of another party, this Agreement
shall not constitute an assignment or an attempted assignment thereof if such
assignment or attempted assignment would constitute a breach thereof.
Warner-Lambert and Horizon shall use their commercially reasonable efforts to
obtain the consent of such other party to the assignment of any such Managed
Care Contract to Horizon in all cases in which such consent is or may be
required for such assignment. If any such consent shall not be obtained,
Warner-Lambert shall cooperate with Horizon in any reasonable arrangement
designed to provide for Horizon the benefits intended to be assigned to Horizon
under the relevant Managed Care Contract, including enforcement at the cost and
for the account of Horizon of any and all right of Warner-Lambert or any of its
Affiliates against the other party thereto arising out of the breach or
cancellation thereof by such other party or otherwise. If and to the extent that
such arrangement cannot be made, Horizon shall have no obligation pursuant to
Section 1.3 or otherwise with respect to any such Managed Care Contract. The
provisions of this Section 5.11 shall not affect the right of Horizon not to
consummate the transactions contemplated by this Agreement if the condition to
its obligations hereunder contained in Section 3.7 has not been fulfilled.

         5.12     NOTIFICATION TO THE TRADE. The parties shall each use their
best efforts to notify Warner-Lambert's customers of the sale of the Product to
Horizon within three (3) Business Days after the Closing Date.

                                       13
<PAGE>   14

                                    ARTICLE 6

                            COVENANTS OF THE PARTIES

         6.1      COVENANTS OF WARNER-LAMBERT. Warner-Lambert covenants and
agrees with Horizon that, at all times from and after the date hereof until the
Closing, Warner-Lambert will comply with all covenants and provisions of this
Section 6.1, except to the extent Horizon may otherwise consent in writing.

                  6.1.1    Investigation by Horizon. Warner-Lambert will provide
Horizon and its Representatives with full access, upon reasonable prior notice
and during normal business hours, to the officers, employees and agents of
Warner-Lambert who have any responsibility for the conduct of the Business, to
Warner-Lambert's accountants and to the Assets.

                  6.1.2    Conduct of Business. Warner-Lambert will operate the
Business only in the ordinary course, consistent with past practice.

                  6.1.3    Fulfillment of Conditions. Warner-Lambert will
execute and deliver at the Closing each operative agreement that Warner-Lambert
is required hereby to execute and deliver as a condition to the Closing, will
take all commercially reasonable steps necessary or desirable and proceed
diligently and in good faith to satisfy each other condition to the obligations
of Horizon contained in this Agreement and will not take or fail to take any
action that could reasonably be expected to result in the nonfulfillment of any
such condition.

         6.2      COVENANTS OF HORIZON. Horizon covenants and agrees with
Warner-Lambert that, at all times from and after the date hereof until the
Closing, Horizon will comply with all covenants and provisions of this Section
6.2, except to the extent Warner-Lambert may otherwise consent in writing.

                  6.2.1    Fulfillment of Conditions. Horizon will execute and
deliver at the Closing each operative agreement that Horizon is hereby required
to execute and deliver as a condition to the Closing, will take all commercially
reasonable steps necessary or desirable and proceed diligently and in good faith
to satisfy each other condition to the obligations of Warner-Lambert contained
in this Agreement and will not take or fail to take any action that could
reasonably be expected to result in the nonfulfillment of any such condition.

                                    ARTICLE 7

                    CONDITIONS TO OBLIGATIONS OF THE PARTIES

         7.1      CONDITIONS TO OBLIGATIONS OF HORIZON. The obligations of
Horizon hereunder to purchase the Assets and to assume and pay, perform and
discharge the Assumed Liabilities are subject to the fulfillment, at or before
the Closing, of each of the following conditions (all or any of which may be
waived in whole or in part by Horizon in its sole discretion):

                  7.1.1    Representations and Warranties. The representations
and warranties made by Warner-Lambert in this Agreement, taken as a whole, shall
be true and correct, in all material respects, on and as of the Closing Date as
though made on and as of the Closing Date

                                       14
<PAGE>   15
or, in the case of representations and warranties made as of a specified date
earlier than the Closing Date, on and as of such earlier date.

                  7.1.2    Performance. Warner-Lambert shall have performed and
complied with, in all material respects, the agreements, covenants and
obligations required by this Agreement to be so performed or complied with by
Warner-Lambert at or before the Closing.

                  7.1.3    Orders and Laws. There shall not be in effect on the
Closing Date any order or law restraining, enjoining or otherwise prohibiting or
making illegal the consummation of any of the transactions contemplated by this
Agreement or any of the operative agreements.

                  7.1.4    Deliveries. Warner-Lambert shall have delivered to
Horizon an Assignment, Assumption and Bill of Sale in the form of Exhibit
7.1.4(a) (the "Assignment, Assumption and Bill of Sale"), a Trademark assignment
in the form of Exhibit 7.1.4(b) and except as otherwise provided herein, such
other documents and instruments as may be necessary to completely sell, convey,
assign, grant, transfer and deliver the Assets to Horizon.

                  7.1.5    Supply Agreement. Warner-Lambert shall have delivered
to Horizon a manufacturing and supply agreement between Warner-Lambert or its
Affiliate and Horizon in the form of Exhibit 7.1.5 (the "Supply Agreement").

                  7.1.6.   Warner-Lambert Assignment Letters. Warner-Lambert
shall have delivered to Horizon letters from Warner-Lambert to the FDA,
transferring all rights and responsibilities under the Registrations to Horizon,
in form reasonably satisfactory to counsel for Horizon (the "Warner-Lambert
Assignment Letters").

         7.2      CONDITIONS TO OBLIGATIONS OF WARNER-LAMBERT. The obligations
of Warner-Lambert hereunder to sell or cause the Selling Affiliates to sell the
Assets are subject to the fulfillment, at or before the Closing, of each of the
following conditions (all or any of which may be waived in whole or in part by
Warner-Lambert in its sole discretion):

                  7.2.1    Representations and Warranties. The representations
and warranties made by Horizon in this Agreement, taken as a whole, shall be
true and correct in all material respects on and as of the Closing Date as
though made on and as of the Closing Date.

                  7.2.2    Performance. Horizon shall have performed and
complied with, in all material respects, the agreements, covenants and
obligations required by this Agreement to be so performed or complied with by
Horizon at or before the Closing.

                  7.2.3    Orders and Laws. There shall not be in effect on the
Closing Date any order or law restraining, enjoining or otherwise prohibiting or
making illegal the consummation of any of the transactions contemplated by this
Agreement or any of the operative agreements.

                  7.2.4    Deliveries. Horizon shall have delivered to
Warner-Lambert the Assignment, Assumption and Bill of Sale and except as
otherwise provided herein, such other documents and instruments as may be
necessary to completely sell, convey, assign, grant, transfer and deliver the
Assets to Horizon.

                                       15
<PAGE>   16

                  7.2.5    Supply Agreement. Horizon shall have delivered to
Warner-Lambert the Supply Agreement.

                  7.2.6.   Horizon Assumption Letters. Horizon shall have
delivered to Warner-Lambert letters from Horizon to the FDA assuming all rights
and responsibilities under the Registrations, in form reasonably satisfactory to
counsel for Warner-Lambert (the "Horizon Assumption Letters").

                                    ARTICLE 8

                                     GENERAL

         8.1      ASSIGNMENT. Until such time as Horizon has discharged all its
payment obligations hereunder, this Agreement may not be assigned by Horizon
without the prior written consent of Warner-Lambert; provided, that Horizon
shall have the right to assign its rights and obligations under this Agreement
to any third party successor to all or substantially all of its entire business.
Warner-Lambert will respond to Horizon's written request for assignment within
forty-five (45) days after receipt of such written request from Horizon. This
Agreement will be binding upon and will inure to the benefit of permitted
assigns and successors. Notwithstanding anything to the contrary in this Section
8.1, Horizon may sublicense the Assets to a third party manufacturer to the
extent and only to the extent necessary to manufacture the Product for Horizon.

         8.2      NOTICES. All notices, requests, demands and other
communications required or permitted under this Agreement shall be in writing
and shall be deemed to have been duly given, made and received on the date when
delivered by hand delivery with receipt acknowledged, or upon the next Business
Day following receipt of telex or telecopy transmission, or upon the third day
after deposit in the United States mail, registered or certified with postage
prepaid, return receipt requested, addressed as set forth below:

         (a)      If to Warner-Lambert:

                  Warner-Lambert Company
                  201 Tabor Road
                  Morris Plains, New Jersey 07950
                  Attn: President, Pharmaceutical Sector
                  Fax: 973-385-4009

                  with a copy to:

                  Warner-Lambert Company
                  201 Tabor Road
                  Morris Plains, New Jersey 07950
                  Attn: Senior Vice President and General Counsel
                  Fax: 973-385-3927

                                       16
<PAGE>   17

         (b)      If to Horizon:

                  First Horizon Pharmaceutical Corporation
                  660 Hembree Parkway, Suite 106
                  Roswell, Georgia  30076
                  Attn:  Vice President, Corporate Development
                  Fax: (770) 442-9594

                  with a copy to:

                  First Horizon Pharmaceutical Corporation
                  660 Hembree Parkway, Suite 106
                  Roswell, Georgia  30076
                  Attn:  Legal Counsel
                  Fax:  (770) 442-9594

Any party may alter the addresses to which communications or copies are to be
sent by giving, notice of such change of address in conformity with the
provisions of this Section for giving notice.

         8.3      SURVIVAL OF REPRESENTATIONS AND WARRANTIES. All
representations and warranties made by Warner-Lambert in this Agreement shall
survive from the Closing Date for a period of two (2) years and terminate
thereafter. All indemnification provisions made by the parties hereto under this
Agreement shall survive indefinitely.

         8.4      SEVERABILITY. If any provision of this Agreement is held to be
invalid or unenforceable for any reason, the remaining provisions will continue
in full force without being impaired or invalidated in any way, and the parties
agree to replace any invalid provision with a valid provision which most closely
approximates the intent and economic effect of the invalid provision.

         8.5      HEADINGS. Headings used in this Agreement are for reference
purposes only and in no way define, limit, construe or describe the scope or
extent of such paragraph, or in any way affect this Agreement.

         8.6      NO WAIVER. No term or provisions hereof shall be deemed
waived, and no breach excused, unless such waiver or consent is in writing and
signed by the party claimed to have waived or consented. The waiver by any party
of a breach of any provision of this Agreement will not operate or be
interpreted as a waiver of any other or subsequent breach.

         8.7      RELATIONSHIP OF THE PARTIES. Nothing in this Agreement should
be construed to create a partnership, agency, joint venture or employer-employee
relationship. None of the parties has the authority to assume or create any
obligation, express or implied, on behalf of any other party.

         8.8      GOVERNING LAW. This Agreement shall be governed and construed
in accordance with the laws of the State of New York. Each party hereby consents
to the personal jurisdiction of the state and federal courts located in New
York.

                                       17
<PAGE>   18
         8.9      ENTIRE AGREEMENT; AMENDMENT. This Agreement, including all
Exhibits and Schedules hereto (which Exhibits and Schedules are hereby
incorporated into and made a part of this Agreement), and the additional
documents required to be delivered on the Closing Date, constitute the final,
complete and exclusive agreement among the parties with respect to the subject
matter hereof and supersede any previous proposals, negotiations, agreements,
arrangements or warranties, whether verbal or written, made among the parties
with respect to such subject matter. This Agreement may be amended or modified
only by mutual agreement in writing of the authorized representatives of the
parties.

         8.10     COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original and all of which shall
together constitute one and the same instrument. This Agreement shall become
binding when one or more counterparts hereof shall bear the signatures of all
parties indicated as signatories hereto.

         8.11     NO THIRD PARTY BENEFICIARY. The terms and provisions of this
Agreement are intended solely for the benefit of each party hereto and their
respective successors or permitted assigns, and it is not the intention of the
parties to confer third-party beneficiary rights upon any other person or
entity.

         8.12     PUBLIC ANNOUNCEMENTS. Warner-Lambert and Horizon will not
issue or make any reports, statements or releases to the public or generally to
the employees, customers, suppliers or other persons or entities with respect to
this Agreement or the transactions contemplated hereby without the consent of
the other parties, which consent shall not be unreasonably withheld. If any
party is unable to obtain the approval of its public report, statement or
release from the other party and such report, statement or release is, in the
opinion of legal counsel to such parties, required by law in order to discharge
such party's disclosure obligations, then such party may make or issue the
legally required report, statement or release and promptly furnish the other
parties with a copy thereof. Warner-Lambert and Horizon will also obtain the
other parties' prior approval of any press release to be issued immediately
following the Closing Date announcing the consummation of the transactions
contemplated by this Agreement.

                                       18
<PAGE>   19

          IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first above written.

                                    WARNER-LAMBERT COMPANY

                                    By:
                                       ----------------------------------------
                                    Name:
                                    Title:

                                    FIRST HORIZON PHARMACEUTICAL CORPORATION

                                    By:
                                       ----------------------------------------
                                    Name:
                                    Title:

                                       19
<PAGE>   20
                                    EXHIBIT A

                                     PRODUCT

Ponstel

<PAGE>   21
                                  EXHIBIT 1.1.1

                           FINISHED PRODUCT INVENTORY

         Item                                                 Quantity
-------------------------------------------------------------------------------
71-540-24 Ponstel 250mg 100's                        16,339 Bottles of 100's

<PAGE>   22

                                  EXHIBIT 1.1.2

                                   TRADEMARKS

<TABLE>
<CAPTION>

             Registration                 Renewal
Trademarks      Number        Country       Date             Owner
----------      ------        -------       ----             -----
<S>          <C>              <C>         <C>            <C>
Ponstel          838249         USA       11/07/2007     Warner-Lambert Company
Ponstel          25773        Puerto      9/06/2004      Warner-Lambert Company
                               Rico
</TABLE>

<PAGE>   23

                                  EXHIBIT 1.1.3

                              REGULATORY APPROVALS

The following NDA relating to the Product:

                              NDA # 15-034 Ponstel

<PAGE>   24

                                  EXHIBIT 2.4.2

                                 PROMISSORY NOTE

US$3,500,000.00
                                                                  April 14, 2000
                                                       Morris Plains, New Jersey

                  FOR VALUE RECEIVED, the undersigned, First Horizon
Pharmaceutical Corporation, a Delaware corporation (the "Borrower"), hereby
promises to pay to the order of Warner-Lambert Company, a Delaware corporation
(the "Lender"), in accordance with the terms hereof, in lawful money of the
United States, the principal sum of Three Million Five Hundred Thousand Dollars
(US$3,500,000.00). The unpaid principal amount of this Note shall be payable by
the Borrower in full, on the earliest of (i) three (3) Business Days following
signing of a definitive asset purchase agreement by Lender and a party other
than Borrower regarding Lender's Cognex business, (ii) three (3) Business Days
following the date on which Borrower notifies Lender that it does not intend to
purchase Lender's Cognex business, (iii) June 1, 2000, in the event that
Borrower has not purchased Lender's Cognex business by such date, other than due
to a delay in receiving clearance from the Federal Trade Commission to proceed
with the purchase of the Cognex business, (iv) three (3) Business Days following
the date on which a definitive agreement between Borrower and Lender for the
Cognex Business is terminated, (v) three (3) Business Days following the date of
the initial public offering of the Borrower and (vi) November 30, 2000. As used
herein, "Business Day" means a day during which banks are generally open for
business in New York.

                  The outstanding principal of this Note, shall be payable by
wire transfer of funds, to the account of the holder of this Note at such
financial institution as such holder designates in writing or, if requested by
such holder, by check payable to the holder of this Note mailed to the address
of such holder as set forth on the records of the Borrower or such other address
as shall be designated in writing by the holder of this Note to the Borrower.

                  Notwithstanding the foregoing, in the event that (i) the
Borrower shall fail to pay any amount of principal when due hereunder, or (ii)
the Borrower shall become insolvent, or admit in writing its inability to pay
its debts as they mature, or make an assignment for the benefit of creditors, or
apply for or consent to the appointment of a trustee, examiner, liquidator or
receiver for the Borrower or for a substantial part of the Borrower's property
or business, or fail to obtain the discharge within thirty (30) days of a
trustee, examiner, liquidator or receiver appointed for the Borrower or for a
substantial part of Borrower's property or business, the Lender at its option
may declare the unpaid principal amount of this Note and any other amount due
hereunder, immediately due and payable.

                  Whenever any payment under this Note shall be due on a day
which is not a Business Day, such payment shall be due on the first Business Day
thereafter.

                  This Note may be paid or prepaid at any time in whole or in
part without premium or penalty.

                  No delay by the Lender in exercising any power or right in
connection herewith shall operate as a waiver of any power or right, nor shall
any single or partial exercise of any power

                                       20
<PAGE>   25
or right preclude other or further exercise thereof, or the exercise of any
other power or right in connection herewith or otherwise; and no waiver whatever
or modification of the terms hereof shall be valid unless set forth in writing
by the Lender and then only to the extent set forth therein.

                  The Borrower may not assign or otherwise transfer any of its
rights or obligations under this Note without the consent of the Lender, and
this Note shall be binding upon the Borrower and its successors and permitted
assigns. The Lender may assign or otherwise transfer all or any part of its
rights under this Note without the consent of the Borrower, and this Note shall
inure to the benefit of the Lender and its successors and assigns.

                  This Note shall be construed in accordance with and governed
by the laws of the State of New York.

                  IN WITNESS THEREOF, the undersigned has caused this Note to be
executed and delivered by a duly authorized officer as of the date first above
written.

                                              FIRST HORIZON PHARMACEUTICAL
                                              CORPORATION

                                              By:
                                                 ------------------------------

<PAGE>   26

                                                                    EXHIBIT 3.10

[****]-CONFIDENTIAL TREATMENT REQUESTED

                             MANAGED CARE CUSTOMERS

PARKE-DAVIS
PONSTEL CONTRACTS
--------------------
ALPHA LISTING
<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------------------------------
                                                    Renewal/       Current        Rights to
                                                  Term. Rights Rebate/  Contract    Change     Assign.   Primary   Admin.
Name      Contact Person Type  Phone Number Term  Both Parties Discount   Price   Price/Rebate Rights   Wholesaler  Fee     Amend.
----------------------------------------------------------------------------------------------------------------------------------
<S>       <C>     <C>    <C>   <C>   <C>    <C>   <C>          <C>      <C>       <C>          <C>      <C>        <C>     <C>
[****]

**[****]
</TABLE>

<PAGE>   27

EXHIBIT 5.9
[****]-CONFIDENTIAL TREATMENT REQUESTED

                               TECHNICAL TRANSFER

MEFENAMIC ACID--API PROCESS
PARKE-DAVIS, HOLLAND, MI PLANT

The follow list details the level of support that Parke-Davis, Holland staff
would provide for the technical transfer of the process used to manufacture this
active pharmaceutical ingredient.

1.   A secrecy agreement would have to be in effect for all parties (including
     Horizon and any third party manufacturer of Horizon) prior to the visit to
     the Holland Plant site.
2.   All technical transfer meetings and process observation would take place at
     the Holland, Michigan plant site during the full scale production batch. It
     will not be possible to provide any support at the customer's facility.
3.   Since equipment availability is quite limited, the production batch would
     be run around the clock in a manner which most efficiently utilizes plant
     resources. The entire effort is expected to take between 1 1/2, and 3 weeks
     to complete.
4.   A production Area Manager and a Chemical Services Chemist will be assigned
     to the customer's team during the technical transfer batch.
5.   One eight hour day will be devoted to a process review with the
     Manufacturing Area Manager and the Chemical Services Chemist the day before
     the Q1 2000 batch is started.
6.   No Parke-Davis documents may be copied/scanned for this transfer, but batch
     records, analytical workcards and raw material specifications will be
     available to the customer team for reading. The customer will of course be
     allowed to take as many notes as needed while on site.
7.   An analyst experienced in this product testing will be made available for a
     separate eight-hour meeting to review testing procedures and experience for
     this product.
8.   Actual in-process and final testing of this product may be observed by the
     customer in Parke-Davis' laboratory. This testing will take place at
     varying times of the day or night to accommodate other production schedules
     at the plant.
9.   The technology transfer would not include any validation work in
     Manufacturing, Quality Assurance or Quality Control, just one production
     batch from start to finish.
10.  The standard yield of a Mefenamic Acid USP lot is [****]. Customer agrees
     to purchase all of the approved Mefenamic Acid in Parke-Davis, Holland's
     inventory after the demonstration lot is complete, at a price of $[****].
11.  The cost for technical support from Manufacturing, Chemical Services and
     Analytical would come to $[****] for on-site support during the
     demonstration batch.

SOLID DOSAGE PROCESS
PARKE-DAVIS, LITITZ, PA PLANT

The follow list details the level of support that Parke-Davis, Lititz staff
would provide for the technical transfer of the process used to manufacture this
solid dosage of Ponstel.

1.       Horizon, Warner-Lambert and any third party manufacturer of Horizon
         shall execute a Nondisclosure Agreement prior to visiting the Lititz
         Plant.

<PAGE>   28
2.       All technical transfer meetings will take place in Lititz at the
         Parke-Davis production facility. No support shall be provided at the
         purchaser's facility or any other facility designated by Purchaser.
3.       Lititz Materials Management will provide dates when production can be
         observed.
4.       One man week of Pharm Tech transfer service will be provided at the
         Lititz manufacturing site.
5.       Validation reports for process, packaging and cleaning will be made
         available when the production process is observed.
6.       Analytical Procedures will be provided for all raw materials and the
         finished product.
7.       Material specifications will be provided for all raw materials and
         packaging supplies.
8.       Provision of the technical transfer service outlined above will be
         subject to a schedule prepared by Warner-Lambert.
9.       The cost for technical support provided by Lititz as outlined above
         will be $12,000.

<PAGE>   29
                                EXHIBIT 7.1.4(A)

                     ASSIGNMENT, ASSUMPTION AND BILL OF SALE

                   THIS GENERAL ASSIGNMENT, ASSUMPTION AND BILL OF SALE is
entered into this 14th day of April, 2000, by and among FIRST HORIZON
PHARMACEUTICAL CORPORATION, a Delaware corporation ("Horizon"), and
WARNER-LAMBERT COMPANY, a Delaware corporation ("Warner-Lambert").

                   WHEREAS, Horizon and Warner-Lambert have entered into a Asset
Purchase Agreement, dated as of April 10, 2000 (the "Asset Purchase Agreement";
capitalized terms not defined herein shall have the meanings ascribed to them in
the Asset Purchase Agreement), pursuant to which Warner-Lambert has agreed to
sell to Horizon and Horizon has agreed to purchase from Warner-Lambert certain
of the assets of Warner-Lambert relating to the Product and Horizon has agreed,
in consideration therefor, to assume certain obligations in connection
therewith;

         NOW, THEREFORE, the parties hereto agree as follows:

         1.       Conveyance and Acceptance. (a) Warner-Lambert hereby
irrevocably sell, assign, and transfer to Horizon, free and clear of all liens,
all of Warner-Lambert's right, title and interest in the Assets and Assumed
Liabilities, other than the Retained Liabilities, as the same shall exist on the
date hereof (collectively, the "Assigned Assets").

         (b)      Horizon hereby accepts the sale, assignment and transfer of
the Assigned Assets.

         2.       Further Assurances. (a) At any time or from time to time after
the date hereof, at Horizon's request and without further consideration,
Warner-Lambert shall execute and deliver to Horizon such other instruments of
sale, transfer, conveyance, assignment and confirmation, provide such materials
and information and take such other actions as Horizon may reasonably deem
necessary or desirable in order more effectively to sell, assign and transfer to
Horizon and to confirm Horizon's title to, all of the Assigned Assets, and, to
the fullest extent permitted by law, to put Horizon in actual possession and
operating control of the Assigned Assets and to assist Horizon in exercising all
rights with respect thereto.

         (b)      Warner-Lambert hereby constitutes and appoints Horizon the
true and lawful attorney of Warner-Lambert, with full power of substitution, in
the name of Warner-Lambert or Horizon, but on behalf of and for the benefit of
Horizon: (i) to demand and receive from time to time any and all of the Assigned
Assets and to make endorsements and give receipts and releases for and in
respect to the same and any part thereof; (ii) to institute, prosecute,
compromise and settle any and all Actions that Horizon may deem proper in order
to collect, assert or enforce any claim, right or title of any kind in or to the
Assigned Assets; (iii) to defend or compromise any and all Actions in respect of
any of the Assigned Assets; and (iv) to do all such acts and things in relation
to the matters set forth in the preceding clauses (i) through (iii) as Horizon
shall deem desirable. Warner-Lambert hereby acknowledges that the appointment
hereby made and the powers hereby granted are coupled with an interest and are
not and shall not be revocable by it in any manner or for any reason. Horizon
shall indemnify and hold harmless Warner-Lambert

<PAGE>   30
and its officers, directors, employees, agents and Affiliates from any and all
Losses caused by or arising out of any breach of law by Horizon in its exercise
of the aforesaid powers.

         3.       Assumption of Liabilities. (a) Horizon hereby undertakes and
agrees from and after the date hereof, subject to the limitations contained
herein, to assume and to pay, perform and discharge when due the Assumed
Liabilities.

                  (b)      Nothing contained herein shall require Horizon to pay
or discharge any debts or obligations expressly assumed hereby so long; as
Horizon shall in good faith contest or cause to be contested the amount or
validity thereof.

                  (c)      Other than as specifically stated above or in the
Asset Purchase Agreement, Horizon assumes no debt, liability or obligation of
Warner-Lambert, including without limitation the Retained Liabilities, by this
General Assignment, Assumption and Bill of Sale, and it is expressly understood
and agreed that all debts, liabilities and obligations not assumed hereby by
Horizon shall remain the sole obligation of Warner-Lambert, its successors and
assigns.

                  (d)      No person other than the Warner-Lambert and its
respective successors and assigns shall have any rights under the provisions of
this Section 3.

         4.       Miscellaneous. (a) This General Assignment, Assumption and
Bill of Sale may be executed in any number of counterparts, each of which will
be deemed an original, but all of which together will constitute one and the
same instrument.

                  (b)      This General Assignment, Assumption and Bill of Sale
shall be governed by, and construed and interpreted in accordance with, the laws
of the State of New York applicable to a contract executed in that State.

                  (c)      This General Assignment, Assumption and Bill of Sale
shall be binding upon and shall inure to the benefit of permitted assigns and
successors.

                  IN WITNESS WHEREOF, this General Assignment, Assumption and
Bill of Sale has been duly executed and delivered by a duly authorized officer
of each party on the day and year first above written.

                                   FIRST HORIZON PHARMACEUTICALS CORPORATION

                                   By:
                                      -----------------------------------------
                                   Name:
                                   Title:

                                   WARNER-LAMBERT COMPANY

                                   By:
                                      -----------------------------------------
                                   Name:
                                   Title:

<PAGE>   31

                                EXHIBIT 7.1.4(B)

                              TRADEMARK ASSIGNMENT

WHEREAS, WARNER-LAMBERT COMPANY, a corporation organized and existing under the
laws of the state of Delaware, with an office and place of business at 201 Tabor
Road, Morris Plains, New Jersey 07950, is the owner of the trademark Ponstel
with Registration Numbers _______ (the "Trademark"), and

WHEREAS, FIRST HORIZON PHARMACEUTICAL CORPORATION, a corporation organized and
existing under the laws of Delaware, with an office and place of business at 660
Hembree Parkway, Suite 106, Roswell, Georgia 30076, pursuant to an Asset
Purchase Agreement dated April __, 2000 among said parties, is desirous of
acquiring all rights, title and interest in and to the Trademark, including the
goodwill associated therewith;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is
hereby acknowledged, said WARNER-LAMBERT COMPANY hereby assigns to said FIRST
HORIZON PHARMACEUTICAL CORPORATION all rights, title and interest in the
Trademark and the goodwill associated therewith.

                                             WARNER-LAMBERT COMPANY

                                             ----------------------------------
                                             Name:
                                             Title:
                                             Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00008-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00008-of-00352.parquet"}]]